logo
Finwire

Finwire

Cantargia selects IL-17 as target for CAN14

The biotechnology company Cantargia has selected IL-17 as the second biological target for the bispecific antibody CAN14.

The drug candidate, which is in preclinical development, is designed to simultaneously inhibit IL1RAP and IL-17 signaling. The aim is to improve the treatment of chronic inflammatory diseases by targeting multiple inflammatory signaling pathways at the same time.

”With CAN14, we aim to raise the bar for treating chronic inflammation by targeting multiple disease-driving signaling pathways with one and the same antibody. The combination of our expertise in IL1RAP with the clinically validated IL-17 signaling pathway provides a strong foundation for developing a differentiated treatment for patients in need of better treatment options”, says Hilde Steineger, CEO of Cantargia.

Share this post

Verifierad av MonsterInsights